A Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare for approximately $7 billion, Axios Pro has confirmed.
Why it matters: The deal is the latest multi-billion move from PE firms in more complicated pharmacy areas.
